Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It will get more difficult and ridiculous to hold up negative sentiments.
*man leaning forward in chair*
"That's what you get for overexcited placebo scores! No silver for you. Bah."
Damn you, Missling!
That is going to be one sick burn coming from someone with a 10% foot in the door. Cool.
buh-bye!
I can accept the additional expenses of a confirmation study if they can be covered by a potential partnership fee or conditional approval revenue.
It is a game changer in AD because the current game sucks so horribly..
Excellent analogy! :D
I agree, high unmet need, orphan disease, highly favorable safety profile, two positive adult trials. Let's see what regulators say.
You're not nervous. That would make you a terrible investor. Even for 2014.
Maybe Blarcamesine can also help with the symptoms MECP2 Duplication Syndrome.
I concur with the author. Thanks for posting!
Public reminder:
Gene therapy is not as easy as it sounds.
Go ask Sarepta:
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-topline-results-embark-global-0
and FUD parrots..
Great to see they are starting to unpack the grab bag of dementias that is "Alzheimer’s disease" and potentially further down the road any other dementia.
FYI: That article is written by none other than our Advisory Board Member Jeffrey Cummings.
Interesting new post on Piotrpeter's blog:
https://piotrpeterblog.com/2023/10/04/the-mystery-of-the-area-under-the-curve-explained-rett-syndrome-results-blarcamesine-avxl/
Excellent post, fully agree!
Can we make this a sticky? :D
Where in the press release does it say ADAS-Cog and CDR-SB are co-primary endpoints?
Odd timing..
Excellent, thanks for the clarification!
Does that also work if the drug was originally approved under orphan drug designation?
Fully agree! Alea iacta est.
You did a fine job yesterday, maui. Looking forward to your meal updates!
I would like to add A2-37 stellar safety profile to that list, short and long term.
Correction: Not a peer reviewed article.
It's a collection of poster abstracts from AAIC 2022:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13147
I would add c.) as a possible avenue for combating neurodegeneration:
Stabilisation of the mitochondrial - ER connection (MAM) - including stabilisation of calcium homeostasis and mitochondrial function.
Is that the best you can do?
"Do you have an increased risk of Neurodegenerative Disease, Alzheimer’s or Dementia in your family?
Find out with our app if Blarcamesine can work for you by starting on it today! It's safe for long term use and works best if taken early."
Ah thanks! Looks like reverserett.org needs to up their DD game..
"Although there is a publication reporting the efficacy of trofinetide in a Fragile X mouse model, there are currently no publications evaluating the efficacy of trofinetide in any animal model of Rett."
That's crazy.
MS Excited As You Are
Correction: Not a peer reviewed article.
It's a collection of poster abstracts from AAIC 2022:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13147
Can you hear them already?
"... BuT, bUt ThErE's DiZzInEsS!!!"
In the same issue there's also this gem:
Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer’s disease: A significant clinical effect but a low benefit/risk ratio
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.064799
Yes, it is:
https://alz-journals.onlinelibrary.wiley.com/hub/journal/15525279/homepage/author-guidelines#AFTERSUBMISSION
AFTER SUBMISSION
Articles are first evaluated by senior editors for suitability for the journal. The goal of this initial evaluation is to provide authors with a quick decision so that if the article is not likely to review well, does not provide novel insights, or does not represent a significant impact, authors are notified so that they can submit elsewhere.
Articles that may be more appropriate for one of the companion journals (A&D DADM or A&D TRCI) are shared with their editors and if their editors are interested in the article a recommendation for transfer is made to the authors.
Articles that meet the initial review by editors are handled by the appropriate section editor. The section editor will solicit a minimum of two independent reviews. At their discretion, editors can solicit more reviews should they feel they are needed. Reviewers can make a recommendation of minor revision, major revision, reject, or accept. Reviewers also provide an impact score from 0-100. The section editor will evaluate the independent reviews and provide a decision recommendation to the editor-in-chief and/or deputy editor if the editor-in-chief is in conflict.
Additional pre-clinical evidence that fixing mitochondrial dysfunction and Calcium homeostasis (downstream action of S1R activation) are promising targets for the treatment of AD:
https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-022-00329-7
Risk of failure potential far outperforming Anavex.